The Economic Burden of Herpes Zoster in Individuals Aged 50 Years or Older and Those With Underlying Conditions in Italy
HZ causes a significant economic impact on the health care system, driven mainly by high costs of medications and hospitalizations among older adults and those with comorbidities, particularly when complicated by PHN.
Authors
- Rita Santacroce (ORCID: https://orcid.org/0000-0003-1377-9183)
- Riccardo Freguja
- Chiara Veronesi (ORCID: https://orcid.org/0000-0003-2852-2022)
- Luca Degli Esposti (ORCID: https://orcid.org/0000-0002-7020-6659)
- Melania Dovizio (ORCID: https://orcid.org/0000-0003-0301-7767)
- Ivan Gentile (ORCID: https://orcid.org/0000-0002-5199-8451)
- Paolo Bonanni (ORCID: https://orcid.org/0000-0002-9448-9059)
- Eleftherios Zarkadoulas (ORCID: https://orcid.org/0009-0003-6940-6367)
- Simona Comparoni (ORCID: https://orcid.org/0000-0003-1923-394X)
- Alessandro Rossi (ORCID: https://orcid.org/0000-0002-0479-9732)
Institutions
- GlaxoSmithKline (Belgium) (BE)
- GlaxoSmithKline (Italy) (IT)
- Health Economics and Outcomes Research (United Kingdom) (GB)
- Società Italiana di Medicina Generale (IT)
- University of Florence (IT)
- University of Naples Federico II (IT)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2024-12-20
- DOI
- https://doi.org/10.1093/ofid/ofae738
- Citations
- 3
- Primary Topic
- Herpesvirus Infections and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.16
Funders
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Novavax
- Moderna
- Shionogi
- Swedish Orphan Biovitrum
- Seqirus
- Sanofi Pasteur